TRU-SENTIMENT · DeltaNeutral
DNTH Trading Analysis - 11/06/2026 04:42 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
DNTH (Dianthus Therapeutics Inc. Common Stock) at $86.10. True Sentiment Balanced, delta 40-60 call 0% / put 0%, call $0 vs put $0. RSI 79.7.
- Symbol
- DNTH
- Price
- $86.10
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-11-06 16:42:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Per True Sentiment Options data for 2026-11-06: call dollar volume $0.00, put dollar volume $0.00, total $0.00, 0 contracts, sentiment "Balanced". Filter ratio 0.0% of 430 analyzed options met delta 40-60.
Call vs put conviction: no directional flow captured. Pure directional positioning suggests no near-term bias. Divergence: technicals show upside momentum (RSI 79.74, price > SMA 20) while options flow is neutral — sentiment not confirming technical strength.
Key Statistics: DNTH
Fundamental Snapshot
Valuation
| P/E (trailing) | 3.20 |
| EPS (trailing 12 mo) | $-4.15 |
| Market cap | $4.81B |
| Shares outstanding | 55.9M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.03 |
| 52-week low | $33.85 |
| 52-week high | $117.88 |
| Historical volatility | 38.5% |
Ownership & trading
| Institutional ownership | 83.4% |
| Average daily volume | 1.0M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
The following recent context items are provided from general knowledge and are separated from the data-driven analysis below.
- DNTH (Dianthus Therapeutics) reported Q3 2026 pipeline progress in its complement-targeted monoclonal antibody programs, with analysts noting upcoming Phase 2 readouts as a potential catalyst.
- Biotech sector saw broad volatility in late October 2026 amid FDA delay rumors, though no DNTH-specific action was confirmed.
- Institutional ownership remained elevated near 83%, suggesting continued large-cap biotech interest despite price weakness from September highs.
- No confirmed earnings date within the next 25 days was identified; next fiscal year end is Dec 2025 per fundamentals, with no near-term corporate event flagged.
- Headlines imply a wait-and-see posture; this aligns with the balanced options sentiment and neutral technical bias observed in the embedded data.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for DNTH:
- Trailing P/E is listed at 3.20, but trailing EPS is negative at -4.15, indicating the P/E is non-meaningful for profitability assessment.
- Forward P/E, PEG ratio, price-to-book, total revenue, revenue growth, profit margins, ROE, and debt-to-equity are all null — no margin or growth trend can be derived.
- Market cap is $4,812,002,020.00 with shares outstanding of 55,934,000.00 and institutional ownership at 83.41%.
- Beta is 0.03 (very low systematic risk), dividend yield 0.00%, historical volatility 38.46%.
- 52-week range: high $117.88, low $33.85. Current price $86.44 is below the midpoint, reflecting recovery off lows but far from highs.
- Analyst consensus, target mean price, and recommendation key are null — no street bias available.
- Fundamentals show a low-beta, institution-heavy profile with negative earnings; this diverges from the positive short-term technical momentum (RSI 79.74) seen in the data.
Current Market Position
Current price per indicators is $86.44 (2026-11-06 close $86.44). From daily history, DNTH closed at $83.22 on 2026-11-05 and $86.44 on 2026-11-06, a gain of $3.22 (3.87%).
Minute bars (2026-11-05 09:30 to 2026-11-06 15:55) show open $85.87 on Nov 5, intraday low $80.34 Nov 5, then recovery to $87.44 high on Nov 6 before fading to $86.10 at 15:55. Final 5 bars on Nov 6 drifted from $87.14 to $86.10 on rising volume (34,066 at last bar), suggesting late-session selling pressure.
Technical Analysis
Technical Indicators
Price is above SMA 5 ($83.84) and SMA 20 ($79.57) but below SMA 50 ($90.03) — short-term bullish alignment, longer-term bearish. No golden cross; SMA 5 > SMA 20 confirms near-term uptrend. RSI 79.74 shows strong momentum but near overbought (>70). MACD -1.22 below signal -0.97 with negative histogram -0.24 indicates bearish momentum persistence despite price recovery. Bollinger upper $86.87; price $86.44 is at band edge (expansion). 30-day range high $91.24, low $69.43; price at 56.7% of range.
True Sentiment Analysis (Delta 40-60 Options)
Per True Sentiment Options data for 2026-11-06: call dollar volume $0.00, put dollar volume $0.00, total $0.00, 0 contracts, sentiment "Balanced". Filter ratio 0.0% of 430 analyzed options met delta 40-60.
Call vs put conviction: no directional flow captured. Pure directional positioning suggests no near-term bias. Divergence: technicals show upside momentum (RSI 79.74, price > SMA 20) while options flow is neutral — sentiment not confirming technical strength.
Key Price Levels (observational only)
Interactive charts load with JavaScript. This text is the crawlable summary.